

Policy #	Policy Name	Type of Change	Brief Description of Policy Change	Reason for Changes
UM ONC_1181	Iron Products		Annual Review	
UM ONC_1200	Torisel (temsirolimus)		Annual Review	
UM ONC_1201	Yervoy (ipilimumab)		Annual Review	
UM ONC_1207	Zelboraf (vemurafenib)		Annual Review	
UM ONC_1249	Mekinist (trametinib)		Annual Review	
UM ONC_1250	Tafinlar (dabrafenib)		Annual Review	
UM ONC_1262	Imbruvica (ibrutinib)		Annual Review	
UM ONC_1264	Zydelig (idelalisib)		Annual Review	
UM ONC_1279	Cotellic (cobimetinib)		Annual Review	
UM ONC_1306	Bavencio (avelumab)		Annual Review	
UM ONC_1313	Alunbrig (brigatinib)		Annual Review	
UM ONC_1315	Rydapt (midostaurin)		Annual Review	
UM ONC_1342	Azedra (iobenguane I-131)		Annual Review	
UM ONC_1356	Elzonris (tagraxofusp)		Annual Review	
UM ONC_1364	Turalio (pexidartinib)		Annual Review	
UM ONC_1366	Inrebic (fedratinib)		Annual Review	
UM ONC_1382	Soliris (eculizumab)		Annual Review	
UM ONC_1385	Tazverik (tazemetostat)		Annual Review	
UM ONC_1386	Ultomiris (ravulizumab)		Annual Review	
UM ONC_1403	Elitek (rasburicase)		Annual Review	
UM ONC_1404	Qinlock (ripretinib)		Annual Review	
UM ONC_1439	Empaveli (pegcetacoplan)		Annual Review	
UM ONC_1441	Rybrevant (amivantamab-vmjw)		Annual Review	
UM ONC_1464	Pyrukynd (mitapivat)		Annual Review	
UM ONC_1478	Zynyz (retifanlimab-dlwr)		Annual Review	